
Please try another search
After-Hours Movers:
Vera Therapeutics Inc (NASDAQ:VERA) 62% LOWER; announced the Phase 2b ORIGIN clinical trial of atacicept in patients with immunoglobulin A nephropathy (IgAN) met its primary endpoint.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) 26% LOWER; announced that the FDA has notified the Company that no action will be taken on the Company's new drug application (NDA) for vonoprazan, a novel potassium-competitive acid blocker (PCAB), under review as a treatment for erosive esophagitis, on or prior to the current Prescription Drug User Fee Act (PDUFA) target action date of January 11, 2023.
Smart Global Holdings Inc (NASDAQ:SGH) 8% HIGHER; reported Q1 EPS of $0.79, $0.20 better than the analyst estimate of $0.59. Revenue for the quarter came in at $465 million versus the consensus estimate of $447.18 million. SMART Global Holdings, Inc. sees Q2 2023 EPS of $0.45-$0.75, versus the consensus of $0.49. SMART Global Holdings, Inc. sees Q2 2023 revenue of $410-460 million, versus the consensus of $432 million.
CarMax (NYSE:KMX) 3% HIGHER; CEO, William Nash, bought 8,220 shares on 12/30/22 at $60.98.
Icosavax Inc (NASDAQ:ICVX) 2% HIGHER; Oppenheimer initiates coverage on with an Outperform rating and a price target of $27.00.
Progress Software Corporation (NASDAQ:PRGS) 1% HIGHER; entered into a definitive agreement to acquire MarkLogic, a leader in managing complex data and metadata and a Vector Capital portfolio company.
Okta, Inc (NASDAQ:OKTA) 1% HIGHER; SMBC Nikko Securities initiates coverage with an Outperform rating and a price target of $90.00.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.